1. BuchbinderSP, KatzMH, HessolNA, O'MalleyPM, HolmbergSD (1994) Long-term HIV-1 infection without immunologic progression. AIDS 8: 1123–1128.
2. LobritzMA, LassenKG, ArtsEJ (2011) HIV-1 replicative fitness in elite controllers. Current opinion in HIV and AIDS 6: 214–220.
3. MellorsJW, KingsleyLA, RinaldoCRJr, ToddJA, HooBS, et al. (1995) Quantitation of HIV-1 RNA in plasma predicts outcome after seroconversion. Annals of internal medicine 122: 573–579.
4. CaoY, QinL, ZhangL, SafritJ, HoDD (1995) Virologic and immunologic characterization of long-term survivors of human immunodeficiency virus type 1 infection. The New England journal of medicine 332: 201–208.
5. DeeksSG, WalkerBD (2007) Human immunodeficiency virus controllers: mechanisms of durable virus control in the absence of antiretroviral therapy. Immunity 27: 406–416.
6. MunozA, KirbyAJ, HeYD, MargolickJB, VisscherBR, et al. (1995) Long-term survivors with HIV-1 infection: incubation period and longitudinal patterns of CD4+ lymphocytes. Journal of acquired immune deficiency syndromes and human retrovirology: official publication of the International Retrovirology Association 8: 496–505.
7. SheppardHW, LangW, AscherMS, VittinghoffE, WinkelsteinW (1993) The characterization of non-progressors: long-term HIV-1 infection with stable CD4+ T-cell levels. AIDS 7: 1159–1166.
8. BakerBM, BlockBL, RothchildAC, WalkerBD (2009) Elite control of HIV infection: implications for vaccine design. Expert opinion on biological therapy 9: 55–69.
9. OkuliczJF, MarconiVC, LandrumML, WegnerS, WeintrobA, et al. (2009) Clinical outcomes of elite controllers, viremic controllers, and long-term nonprogressors in the US Department of Defense HIV natural history study. The Journal of infectious diseases 200: 1714–1723.
10. LambotteO, BoufassaF, MadecY, NguyenA, GoujardC, et al. (2005) HIV controllers: a homogeneous group of HIV-1-infected patients with spontaneous control of viral replication. Clinical infectious diseases: an official publication of the Infectious Diseases Society of America 41: 1053–1056.
11. McLarenPJ, RipkeS, PelakK, WeintrobAC, PatsopoulosNA, et al. (2012) Fine-mapping classical HLA variation associated with durable host control of HIV-1 infection in African Americans. Human molecular genetics 21: 4334–4347.
12. O'ConnellKA, BaileyJR, BlanksonJN (2009) Elucidating the elite: mechanisms of control in HIV-1 infection. Trends in pharmacological sciences 30: 631–637.
13. StreeckH, NixonDF (2010) T cell immunity in acute HIV-1 infection. The Journal of infectious diseases 202 Suppl 2: S302–308.
14. JurriaansS, Van GemenB, WeverlingGJ, Van StrijpD, NaraP, et al. (1994) The natural history of HIV-1 infection: virus load and virus phenotype independent determinants of clinical course? Virology 204: 223–233.
15. ChoperaDR, WoodmanZ, MlisanaK, MlotshwaM, MartinDP, et al. (2008) Transmission of HIV-1 CTL escape variants provides HLA-mismatched recipients with a survival advantage. PLoS pathogens 4: e1000033.
16. CrawfordH, LummW, LeslieA, SchaeferM, BoerasD, et al. (2009) Evolution of HLA-B*5703 HIV-1 escape mutations in HLA-B*5703-positive individuals and their transmission recipients. J Exp Med 206: 909–921.
17. GoepfertPA, LummW, FarmerP, MatthewsP, PrendergastA, et al. (2008) Transmission of HIV-1 Gag immune escape mutations is associated with reduced viral load in linked recipients. The Journal of experimental medicine 205: 1009–1017.
18. PrinceJL, ClaiborneDT, CarlsonJM, SchaeferM, YuT, et al. (2012) Role of Transmitted Gag CTL Polymorphisms in Defining Replicative Capacity and Early HIV-1 Pathogenesis. PLoS pathogens 8: e1003041.
19. TangJ, MalhotraR, SongW, BrillI, HuL, et al. (2010) Human leukocyte antigens and HIV type 1 viral load in early and chronic infection: predominance of evolving relationships. PloS one 5: e9629.
20. WrightJK, NaidooVL, BrummeZL, PrinceJL, ClaiborneDT, et al. (2012) Impact of HLA-B*81-associated mutations in HIV-1 Gag on viral replication capacity. Journal of virology 86: 3193–3199.
21. YueL, PrenticeHA, FarmerP, SongW, HeD, et al. (2013) Cumulative Impact of Host and Viral Factors on HIV-1 Viral-Load Control during Early Infection. Journal of virology 87: 708–715.
22. PereyraF, JiaX, McLarenPJ, TelentiA, de BakkerPI, et al. (2010) The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science 330: 1551–1557.
23. FellayJ, ShiannaKV, GeD, ColomboS, LedergerberB, et al. (2007) A whole-genome association study of major determinants for host control of HIV-1. Science 317: 944–947.
24. FellayJ, GeD, ShiannaKV, ColomboS, LedergerberB, et al. (2009) Common genetic variation and the control of HIV-1 in humans. PLoS Genet 5: e1000791.
25. TangJ, TangS, LobashevskyE, ZuluI, AldrovandiG, et al. (2004) HLA allele sharing and HIV type 1 viremia in seroconverting Zambians with known transmitting partners. AIDS Research and Human Retroviruses 20: 19–25.
26. GoulderPJ, WatkinsDI (2008) Impact of MHC class I diversity on immune control of immunodeficiency virus replication. Nature reviews Immunology 8: 619–630.
27. LeslieA, MatthewsPC, ListgartenJ, CarlsonJM, KadieC, et al. (2010) Additive contribution of HLA class I alleles in the immune control of HIV-1 infection. Journal of virology 84: 9879–9888.
28. MatthewsPC, AdlandE, ListgartenJ, LeslieA, MkhwanaziN, et al. (2011) HLA-A*7401-mediated control of HIV viremia is independent of its linkage disequilibrium with HLA-B*5703. Journal of immunology 186: 5675–5686.
29. KiepielaP, NgumbelaK, ThobakgaleC, RamduthD, HoneyborneI, et al. (2007) CD8+ T-cell responses to different HIV proteins have discordant associations with viral load. Nature medicine 13: 46–53.
30. ShacklettBL (2010) Immune responses to HIV and SIV in mucosal tissues: ‘location, location, location’. Current opinion in HIV and AIDS 5: 128–134.
31. GoulderPJ, PhillipsRE, ColbertRA, McAdamS, OggG, et al. (1997) Late escape from an immunodominant cytotoxic T-lymphocyte response associated with progression to AIDS. Nature medicine 3: 212–217.
32. LeslieAJ, PfafferottKJ, ChettyP, DraenertR, AddoMM, et al. (2004) HIV evolution: CTL escape mutation and reversion after transmission. Nat Med 10: 282–289.
33. GoulderPJ, WatkinsDI (2004) HIV and SIV CTL escape: implications for vaccine design. Nature reviews Immunology 4: 630–640.
34. BorrowP, LewickiH, WeiX, HorwitzMS, PefferN, et al. (1997) Antiviral pressure exerted by HIV-1-specific cytotoxic T lymphocytes (CTLs) during primary infection demonstrated by rapid selection of CTL escape virus. Nature medicine 3: 205–211.
35. JonesNA, WeiX, FlowerDR, WongM, MichorF, et al. (2004) Determinants of human immunodeficiency virus type 1 escape from the primary CD8+ cytotoxic T lymphocyte response. The Journal of experimental medicine 200: 1243–1256.
36. BrockmanMA, BrummeZL, BrummeCJ, MiuraT, SelaJ, et al. (2010) Early selection in Gag by protective HLA alleles contributes to reduced HIV-1 replication capacity that may be largely compensated for in chronic infection. Journal of virology 84: 11937–11949.
37. MiuraT, BrockmanMA, SchneidewindA, LobritzM, PereyraF, et al. (2009) HLA-B57/B*5801 human immunodeficiency virus type 1 elite controllers select for rare gag variants associated with reduced viral replication capacity and strong cytotoxic T-lymphocyte [corrected] recognition. Journal of virology 83: 2743–2755.
38. BaileyJR, WilliamsTM, SilicianoRF, BlanksonJN (2006) Maintenance of viral suppression in HIV-1-infected HLA-B*57+ elite suppressors despite CTL escape mutations. The Journal of experimental medicine 203: 1357–1369.
39. AlizonS, von WylV, StadlerT, KouyosRD, YerlyS, et al. (2010) Phylogenetic approach reveals that virus genotype largely determines HIV set-point viral load. PLoS pathogens 6: e1001123.
40. HechtFM, HartogensisW, BraggL, BacchettiP, AtchisonR, et al. (2010) HIV RNA level in early infection is predicted by viral load in the transmission source. AIDS 24: 941–945.
41. HollingsworthTD, LaeyendeckerO, ShirreffG, DonnellyCA, SerwaddaD, et al. (2010) HIV-1 transmitting couples have similar viral load set-points in Rakai, Uganda. PLoS Pathog 6: e1000876.
42. LylesRH, MunozA, YamashitaTE, BazmiH, DetelsR, et al. (2000) Natural history of human immunodeficiency virus type 1 viremia after seroconversion and proximal to AIDS in a large cohort of homosexual men. Multicenter AIDS Cohort Study. The Journal of infectious diseases 181: 872–880.
43. WrightJK, NovitskyV, BrockmanMA, BrummeZL, BrummeCJ, et al. (2011) Influence of Gag-protease-mediated replication capacity on disease progression in individuals recently infected with HIV-1 subtype C. Journal of virology 85: 3996–4006.
44. MiuraT, BrockmanMA, BrummeCJ, BrummeZL, CarlsonJM, et al. (2008) Genetic characterization of human immunodeficiency virus type 1 in elite controllers: lack of gross genetic defects or common amino acid changes. Journal of virology 82: 8422–8430.
45. MiuraT, BrockmanMA, BrummeZL, BrummeCJ, PereyraF, et al. (2009) HLA-associated alterations in replication capacity of chimeric NL4-3 viruses carrying gag-protease from elite controllers of human immunodeficiency virus type 1. Journal of virology 83: 140–149.
46. MiuraT, BrummeZL, BrockmanMA, RosatoP, SelaJ, et al. (2010) Impaired replication capacity of acute/early viruses in persons who become HIV controllers. Journal of virology 84: 7581–7591.
47. LassenKG, LobritzMA, BaileyJR, JohnstonS, NguyenS, et al. (2009) Elite suppressor-derived HIV-1 envelope glycoproteins exhibit reduced entry efficiency and kinetics. PLoS pathogens 5: e1000377.
48. BlanksonJN, BaileyJR, ThayilS, YangHC, LassenK, et al. (2007) Isolation and characterization of replication-competent human immunodeficiency virus type 1 from a subset of elite suppressors. Journal of virology 81: 2508–2518.
49. BoerasDI, HraberPT, HurlstonM, Evans-StrickfadenT, BhattacharyaT, et al. (2011) Role of donor genital tract HIV-1 diversity in the transmission bottleneck. Proceedings of the National Academy of Sciences of the United States of America 108: E1156–1163.
50. DerdeynCA, DeckerJM, Bibollet-RucheF, MokiliJL, MuldoonM, et al. (2004) Envelope-constrained neutralization-sensitive HIV-1 after heterosexual transmission. Science 303: 2019–2022.
51. HaalandRE, HawkinsPA, Salazar-GonzalezJ, JohnsonA, TichacekA, et al. (2009) Inflammatory genital infections mitigate a severe genetic bottleneck in heterosexual transmission of subtype A and C HIV-1. PLoS pathogens 5: e1000274.
52. RousseauCM, BirdittBA, McKayAR, StoddardJN, LeeTC, et al. (2006) Large-scale amplification, cloning and sequencing of near full-length HIV-1 subtype C genomes. Journal of virological methods 136: 118–125.
53. Salazar-GonzalezJF, SalazarMG, KeeleBF, LearnGH, GiorgiEE, et al. (2009) Genetic identity, biological phenotype, and evolutionary pathways of transmitted/founder viruses in acute and early HIV-1 infection. The Journal of experimental medicine 206: 1273–1289.
54. GoonetillekeN, LiuMK, Salazar-GonzalezJF, FerrariG, GiorgiE, et al. (2009) The first T cell response to transmitted/founder virus contributes to the control of acute viremia in HIV-1 infection. The Journal of experimental medicine 206: 1253–1272.
55. BarKJ, TsaoCY, IyerSS, DeckerJM, YangY, et al. (2012) Early low-titer neutralizing antibodies impede HIV-1 replication and select for virus escape. PLoS pathogens 8: e1002721.
56. BaalwaJ, WangS, ParrishNF, DeckerJM, KeeleBF, et al. (2013) Molecular identification, cloning and characterization of transmitted/founder HIV-1 subtype A, D and A/D infectious molecular clones. Virology 436: 33–48.
57. BoutwellCL, CarlsonJM, LinTH, SeeseA, PowerKA, et al. (2013) Frequent and Variable Cytotoxic-T-Lymphocyte Escape-associated Fitness Costs in the Human Immunodeficiency Virus Type 1 Subtype B Gag Proteins. Journal of virology
58. BrockmanMA, SchneidewindA, LahaieM, SchmidtA, MiuraT, et al. (2007) Escape and compensation from early HLA-B57-mediated cytotoxic T-lymphocyte pressure on human immunodeficiency virus type 1 Gag alter capsid interactions with cyclophilin A. Journal of virology 81: 12608–12618.
59. CrawfordH, PradoJG, LeslieA, HueS, HoneyborneI, et al. (2007) Compensatory mutation partially restores fitness and delays reversion of escape mutation within the immunodominant HLA-B*5703-restricted Gag epitope in chronic human immunodeficiency virus type 1 infection. Journal of virology 81: 8346–8351.
60. JinX, BauerDE, TuttletonSE, LewinS, GettieA, et al. (1999) Dramatic rise in plasma viremia after CD8(+) T cell depletion in simian immunodeficiency virus-infected macaques. The Journal of experimental medicine 189: 991–998.
61. SchmitzJE, KurodaMJ, SantraS, SassevilleVG, SimonMA, et al. (1999) Control of viremia in simian immunodeficiency virus infection by CD8+ lymphocytes. Science 283: 857–860.
62. LiuMK, HawkinsN, RitchieAJ, GanusovVV, WhaleV, et al. (2013) Vertical T cell immunodominance and epitope entropy determine HIV-1 escape. J Clin Invest 123: 380–393.
63. MotheB, LlanoA, IbarrondoJ, DanielsM, MirandaC, et al. (2011) Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med 9: 208.
64. PayneRP, KloverprisH, SachaJB, BrummeZ, BrummeC, et al. (2010) Efficacious early antiviral activity of HIV Gag- and Pol-specific HLA-B 2705-restricted CD8+ T cells. Journal of virology 84: 10543–10557.
65. FerrariG, KorberB, GoonetillekeN, LiuMK, TurnbullEL, et al. (2011) Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS pathogens 7: e1001273.
66. DerdeynCA, DeckerJM, SfakianosJN, WuX, O'BrienWA, et al. (2000) Sensitivity of human immunodeficiency virus type 1 to the fusion inhibitor T-20 is modulated by coreceptor specificity defined by the V3 loop of gp120. J Virol 74: 8358–8367.
67. WeiX, DeckerJM, LiuH, ZhangZ, AraniRB, et al. (2002) Emergence of resistant human immunodeficiency virus type 1 in patients receiving fusion inhibitor (T-20) monotherapy. Antimicrob Agents Chemother 46: 1896–1905.
68. BorrowP, LewickiH, HahnBH, ShawGM, OldstoneMB (1994) Virus-specific CD8+ cytotoxic T-lymphocyte activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. Journal of virology 68: 6103–6110.
69. KoupRA, SafritJT, CaoY, AndrewsCA, McLeodG, et al. (1994) Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. Journal of virology 68: 4650–4655.
70. TurnbullEL, WongM, WangS, WeiX, JonesNA, et al. (2009) Kinetics of expansion of epitope-specific T cell responses during primary HIV-1 infection. Journal of immunology 182: 7131–7145.
71. FiebigEW, WrightDJ, RawalBD, GarrettPE, SchumacherRT, et al. (2003) Dynamics of HIV viremia and antibody seroconversion in plasma donors: implications for diagnosis and staging of primary HIV infection. AIDS 17: 1871–1879.
72. HatanoH, DelwartEL, NorrisPJ, LeeTH, Dunn-WilliamsJ, et al. (2009) Evidence for persistent low-level viremia in individuals who control human immunodeficiency virus in the absence of antiretroviral therapy. Journal of virology 83: 329–335.
73. NavisM, SchellensI, van BaarleD, BorghansJ, van SwietenP, et al. (2007) Viral replication capacity as a correlate of HLA B57/B5801-associated nonprogressive HIV-1 infection. Journal of immunology 179: 3133–3143.
74. JanssenEM, LemmensEE, WolfeT, ChristenU, von HerrathMG, et al. (2003) CD4+ T cells are required for secondary expansion and memory in CD8+ T lymphocytes. Nature 421: 852–856.
75. BettsMR, NasonMC, WestSM, De RosaSC, MiguelesSA, et al. (2006) HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. Blood 107: 4781–4789.
76. MiguelesSA, OsborneCM, RoyceC, ComptonAA, JoshiRP, et al. (2008) Lytic granule loading of CD8+ T cells is required for HIV-infected cell elimination associated with immune control. Immunity 29: 1009–1021.
77. Ribeiro-dos-SantosP, TurnbullEL, MonteiroM, LegrandA, ConrodK, et al. (2012) Chronic HIV infection affects the expression of the 2 transcription factors required for CD8 T-cell differentiation into cytolytic effectors. Blood 119: 4928–4938.
78. AppsR, QiY, CarlsonJM, ChenHY, GaoXJ, et al. (2013) Influence of HLA-C Expression Level on HIV Control. Science 340: 87–91.
79. AddoMM, YuXG, RathodA, CohenD, EldridgeRL, et al. (2003) Comprehensive epitope analysis of human immunodeficiency virus type 1 (HIV-1)-specific T-cell responses directed against the entire expressed HIV-1 genome demonstrate broadly directed responses, but no correlation to viral load. Journal of virology 77: 2081–2092.
80. GanusovVV, GoonetillekeN, LiuMK, FerrariG, ShawGM, et al. (2011) Fitness costs and diversity of the cytotoxic T lymphocyte (CTL) response determine the rate of CTL escape during acute and chronic phases of HIV infection. Journal of virology 85: 10518–10528.
81. van DeutekomHW, WijnkerG, de BoerRJ (2013) The rate of immune escape vanishes when multiple immune responses control an HIV infection. Journal of immunology 191: 3277–3286.
82. MuddPA, EricsenAJ, BurwitzBJ, WilsonNA, O'ConnorDH, et al. (2012) Escape from CD8(+) T cell responses in Mamu-B*00801(+) macaques differentiates progressors from elite controllers. Journal of immunology 188: 3364–3370.
83. WangYE, LiB, CarlsonJM, StreeckH, GladdenAD, et al. (2009) Protective HLA class I alleles that restrict acute-phase CD8+ T-cell responses are associated with viral escape mutations located in highly conserved regions of human immunodeficiency virus type 1. Journal of virology 83: 1845–1855.
84. Gasper-SmithN, CrossmanDM, WhitesidesJF, MensaliN, OttingerJS, et al. (2008) Induction of plasma (TRAIL), TNFR-2, Fas ligand, and plasma microparticles after human immunodeficiency virus type 1 (HIV-1) transmission: implications for HIV-1 vaccine design. Journal of virology 82: 7700–7710.
85. FrletaD, OchoaCE, KramerHB, KhanSA, StaceyAR, et al. (2012) HIV-1 infection-induced apoptotic microparticles inhibit human DCs via CD44. J Clin Invest 122: 4685–4697.
86. OverbaughJ, MorrisL (2012) The Antibody Response against HIV-1. Cold Spring Harbor perspectives in medicine 2: a007039.
87. MontefioriDC, PantaleoG, FinkLM, ZhouJT, ZhouJY, et al. (1996) Neutralizing and infection-enhancing antibody responses to human immunodeficiency virus type 1 in long-term nonprogressors. The Journal of infectious diseases 173: 60–67.
88. CarotenutoP, LooijD, KeldermansL, de WolfF, GoudsmitJ (1998) Neutralizing antibodies are positively associated with CD4+ T-cell counts and T-cell function in long-term AIDS-free infection. AIDS 12: 1591–1600.
89. CeciliaD, KleebergerC, MunozA, GiorgiJV, Zolla-PaznerS (1999) A longitudinal study of neutralizing antibodies and disease progression in HIV-1-infected subjects. The Journal of infectious diseases 179: 1365–1374.
90. PereyraF, AddoMM, KaufmannDE, LiuY, MiuraT, et al. (2008) Genetic and immunologic heterogeneity among persons who control HIV infection in the absence of therapy. The Journal of infectious diseases 197: 563–571.
91. Doria-RoseNA, KleinRM, ManionMM, O'DellS, PhogatA, et al. (2009) Frequency and phenotype of human immunodeficiency virus envelope-specific B cells from patients with broadly cross-neutralizing antibodies. Journal of virology 83: 188–199.
92. LambotteO, FerrariG, MoogC, YatesNL, LiaoHX, et al. (2009) Heterogeneous neutralizing antibody and antibody-dependent cell cytotoxicity responses in HIV-1 elite controllers. AIDS 23: 897–906.
93. MahalanabisM, JayaramanP, MiuraT, PereyraF, ChesterEM, et al. (2009) Continuous viral escape and selection by autologous neutralizing antibodies in drug-naive human immunodeficiency virus controllers. Journal of virology 83: 662–672.
94. MurphyMK, YueL, PanR, BoliarS, SethiA, et al. (2013) Viral Escape from Neutralizing Antibodies in Early Subtype A HIV-1 Infection Drives an Increase in Autologous Neutralization Breadth. PLoS Pathog 9: e1003173.
95. OverbaughJ, RudenseyLM (1992) Alterations in potential sites for glycosylation predominate during evolution of the simian immunodeficiency virus envelope gene in macaques. Journal of virology 66: 5937–5948.
96. ChackerianB, RudenseyLM, OverbaughJ (1997) Specific N-linked and O-linked glycosylation modifications in the envelope V1 domain of simian immunodeficiency virus variants that evolve in the host alter recognition by neutralizing antibodies. Journal of virology 71: 7719–7727.
97. RichmanDD, WrinT, LittleSJ, PetropoulosCJ (2003) Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proceedings of the National Academy of Sciences of the United States of America 100: 4144–4149.
98. WeiX, DeckerJM, WangS, HuiH, KappesJC, et al. (2003) Antibody neutralization and escape by HIV-1. Nature 422: 307–312.
99. LiB, DeckerJM, JohnsonRW, Bibollet-RucheF, WeiX, et al. (2006) Evidence for potent autologous neutralizing antibody titers and compact envelopes in early infection with subtype C human immunodeficiency virus type 1. Journal of virology 80: 5211–5218.
100. BunnikEM, PisasL, van NuenenAC, SchuitemakerH (2008) Autologous neutralizing humoral immunity and evolution of the viral envelope in the course of subtype B human immunodeficiency virus type 1 infection. Journal of virology 82: 7932–7941.
101. MoorePL, GrayES, MorrisL (2009) Specificity of the autologous neutralizing antibody response. Current opinion in HIV and AIDS 4: 358–363.
102. RongR, LiB, LynchRM, HaalandRE, MurphyMK, et al. (2009) Escape from autologous neutralizing antibodies in acute/early subtype C HIV-1 infection requires multiple pathways. PLoS pathogens 5: e1000594.
103. GnanakaranS, LangD, DanielsM, BhattacharyaT, DerdeynCA, et al. (2007) Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. Journal of virology 81: 4886–4891.
104. LynchRM, RongR, BoliarS, SethiA, LiB, et al. (2011) The B cell response is redundant and highly focused on V1V2 during early subtype C infection in a Zambian seroconverter. J Virol 85: 905–915.
105. TraskSA, DerdeynCA, FideliU, ChenY, MelethS, et al. (2002) Molecular epidemiology of human immunodeficiency virus type 1 transmission in a heterosexual cohort of discordant couples in Zambia. Journal of virology 76: 397–405.
106. KeeleBF, GiorgiEE, Salazar-GonzalezJF, DeckerJM, PhamKT, et al. (2008) Identification and characterization of transmitted and early founder virus envelopes in primary HIV-1 infection. Proceedings of the National Academy of Sciences of the United States of America 105: 7552–7557.
107. RoedererM, KoupRA (2003) Optimized determination of T cell epitope responses. Journal of immunological methods 274: 221–228.
108. PantaleoG, SoudeynsH, DemarestJF, VaccarezzaM, GraziosiC, et al. (1997) Evidence for rapid disappearance of initially expanded HIV-specific CD8+ T cell clones during primary HIV infection. Proceedings of the National Academy of Sciences of the United States of America 94: 9848–9853.
109. PossM, GosinkJ, ThomasE, KreissJK, Ndinya-AcholaJ, et al. (1997) Phylogenetic evaluation of Kenyan HIV type 1 isolates. AIDS Res Hum Retroviruses 13: 493–499.